What's in Novartis Vaccines's pipeline?

Novartis Vaccines has 12 drugs in our index: 8 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Novartis Vaccines's portfolio?

Top competitors by shared drug class: CHU de Quebec-Universite Laval, CanSino Biologics Inc., Canadian Immunization Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/novartis-vaccines.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Novartis Vaccines — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novartis Vaccines pipeline: 8 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 3 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Meningococcal B vaccine	Meningococcal B vaccine	marketed
Varicella	Varicella	marketed			Other
MenC	MenC	marketed	Conjugate vaccine	Capsular polysaccharide of Neisseria meningitidis serogroup C	Immunology
Rabies	Rabies	marketed			Other
Fluad_MF59-adjuvanted trivalent influenza subunit vaccine	Fluad_MF59-adjuvanted trivalent influenza subunit vaccine	marketed
Haemophilus influenza type b conjugate vaccine	Haemophilus influenza type b conjugate vaccine	marketed
Cell-derived influenza vaccine	Cell-derived influenza vaccine	marketed
TBE vaccine for adults	TBE vaccine for adults	marketed
Zagreb	Zagreb	phase 3			Other
MMR-V	MMR-V	phase 3
Adjuvanted seasonal influenza vaccine	Adjuvanted seasonal influenza vaccine	phase 3

Therapeutic area mix

Other · 3
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

CHU de Quebec-Universite Laval · 1 shared drug class
CanSino Biologics Inc. · 1 shared drug class
Canadian Immunization Research Network · 1 shared drug class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Heinrich-Heine University, Duesseldorf · 1 shared drug class
International Vaccine Institute · 1 shared drug class
Beijing Minhai Biotechnology Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Novartis Vaccines:

Cite this brief

Drug Landscape (2026). Novartis Vaccines — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/novartis-vaccines. Accessed 2026-05-16.